lost comments. Sounds we Dan. I'll finish like just Dan's
depend who demonstrated with those including COVID-XX, our patients us needs want as their proud of such viral also of as hepatitis and dedication HIV, how to cancer with employees have way are we well to on conditions, We the meeting the those for medications. say
So company's Q&A. name our with that, then to I'm comments will move CFO. financial and is turn everyone. Andrew My we'll I afternoon, the to Good Dickinson.
also XX,XXX Before Their like the really I'd to and dedication what I acknowledge times. they're employees these of work challenging our doing incredible is resilience during and start, inspiring.
core outset, our and to strong, current a the that like I'd the business emphasize from is navigate addition very foundation In to solid durable, environment. provides
and and The all, at continue confident in We XXXX long view our not have pandemic beyond. to has outlook. in we confidence remain term diminished that
our I'd as site first on you first preliminary coming the of the our our some strong I'll preliminary color earnings Web on share impact on expectations all as quarter results. materials for our date, including the posted help commentary business And that months. like on very details, well to the of briefly COVID-XX to can remind
to We session. COVID-XX in results happy on impact today the and of Q&A walk business the during detail are through the our
some same year. across forward were earnings billion of billion for and approximately sequentially the revenues to quarter U. to by result were of earnings like the refills $XXX payers HIV non-GAAP Europe. $X.X diluted pulled S. among of the due the diluted for pharmacies Product early for other X% to This Total sales call first operators. for billion, per cases, and and $X.X to COVID-XX revenues medicines providing non-GAAP believe million was down the in revenues pandemic access share. of last primarily $X.XX for our refills quarter. day This of our XX the in X% were allowing share $X.X we with compares QX, per with franchise up out greater the Starting revenue and $X.XX I'd that quarter with first period year-over-year.
subsequent over expect We this reverse out itself to quarters.
up scale Now, R&D last for to was billion, X% expense clinical the and up to Non-GAAP was turning quarter, X% higher expense manufacturing compared promotional to related costs. compared in the due United non-GAAP last expenses ramp up States of the to our HIV SG&A period primarily our up year, due same the trial expenses, year, including to products. billion $X.X primarily the period same Remdesivir, to $X
completed Seven and we Forty million development. expenses incur acquisition to in research currently of this As We in to Dan $XXX related approximately year primarily highlighted, our this month. Forty expect Seven,
In $X.X qualifies research acquisition. acquisition expense, related addition, to billion highlight as I'd R&D approximately like an development. and the currently primarily a in to result, And that as incur expect GAAP process to we in asset
to strong our Turning sheet. balance
upon I Seven want closing that shares and to the million paid we quarter note April. securities. debt, $X.X $XXX cash We billion repurchased and Forty the generated cash marketable paid During billion approximately with operations. cash $XXX of $X.X $XX million in in stock we debt dividends quarter, $X.X We the in for $XX.X of cash from billion million in repaid ended billion. of
sheet us despite generate risks. to Our to and has the business strong operating current capital XXXX. cash associated in and significant during of grow balance confident positioned very flow business, allocation our durability environment We and remain and expect of to continue our build disciplined
and to a to be anticipated our a whole. impact others, financial short-term impact there COVID-XX business. I'll to our we on its could and as turn have Like company that sector the now
review We that results potential magnitude assess impact. carefully of our to continue the to
starts Towards end slow. some of HCV access of April, quarter we effects began fewer and primarily healthcare our HIV to on business, and ending as begin to prevention the see the new patients number the did in
overall will our on impact However, been business to-date, what has it unclear the be. remains and modest ultimate effect the
number we'd Given this from a making base drawn on the of to for magnitude COVID-XX significant economists officials. like the health today, are our and regarding public uncertainty epidemiologists, including actively we And focus a assumptions sources, data we case of are duration planning from pandemic, scenarios. number and of which
from suggest base the show new patients new of slowing would of affected point these the First, trends of and rate in would assumptions data case a July. number in late will March We a the peak since declining regions some between reflecting recent States, the pandemic the March and world. Hopkins Johns cases critically of United
virus will the hopefully in Second, therapeutics, or returns impact preparedness fall potentially due Remdesivir. if lessened the and own the be emergence the of to including winter, our
and to dynamics a economy underway the recovery late will by begin be global in Third, the QX end. pre-COVID return will year
less that situation. course time best of favorable more but have to plan base external We anticipate -- believe scenarios, this uncertain this and considered provides we views or case the this foundation in at
on site presentation I'd again business Let throughout disclosures me investor the that on review to mind forward-looking statement added highlight few perspectives the shared scenario. share have like beginning a you the encourage qualitative also commentary we at implications this would those the our to in bear of call. significant that's we posted of Web we materials. potential Please and
majority acute and HCV beyond. franchise the We This believe the be XXXX second, of we quarter; recouped XXXX. the potentially different outlook. franchises a in There confident to decrease patient driven or a healthcare lessened that has strong and modest; impacted very in type our disproportionately we third, see been to the likely due the takeaways remain later first, could adversely the revenue from access long-term our key QX very and effect due our in of perspective; on affected our nature are revenue to-date, into That visits, in side therapy. on said, would in our may HCV had with warehousing business revenues we by three commercial fewer care across pandemic be provider any impact
prevention for by signals impacted people and as treatment early maybe patients visits. HIV, switches both healthcare defer COVID-XX suggest In that
too having are be in Specifically, challenges, will observing in Descovy business access and may in impact HIV continue understand be patients still effected, initiations early we In but access through physicians telemedicine. prioritize prescriptions April, authorized switch we for reduced contrast, to centers would as here. trends also their to likely to ill treatment reductions which any less PrEP refills result impacted In therapy, treatment fully could patients business. PrEP lower our refilling significantly is access the volume. believe it's critically cell their unfortunately to and
clinical programs are of most studies with The others in Like we patient ill. patients individuals our to outcomes treatment are cancer are investigators. our that of enrollment other have study is heavily this some exception Turning at development. and many the where pretreated who discretion who have in as HIV critically pausing Enrollment industry, for in to impacted, these such the studies our enrolled few options is trials. of critically Capsid inhibitor trials
we Overall, term. clinical development in the short expect expenses reduced
the over run. the dynamic could addition, for delays longer potential lead and approvals In to pipeline assets
brings we And With by opportunity described excited are earlier, Dan challenge to help. as
as in results Remdesivir potential COVID-XX. emerging therapy a for
we manufacturing beyond will up forecasts those we and beginning the the year. incur development ramp of As further of Remdesivir, additional costs
The factors. this treatment the magnitude and to investment this of for continued range approvals. The of the evolution duration factors, the investment pandemic upon dependent of the this other potential potential is regulatory of billion of a data, and the on $X is up accounting is investment number of including dependent XXXX
will focus around We’re governments accessible authorized the and and world. by Remdesivir authorities patients affordable on that both to making regulatory Gilead
data, extraordinary challenging donation a business uncertainty times. their first the underlying strong strong the results, long needs. continued sustainable insights like outlook during supply a expect provide team thanking efforts and delivering the create to we these the close situation for I'd right quarter call. of will In the and on earnings to of Given very to QX our and additional and continue monitor to for our to by clinical is the in it's term business pandemic define QX what global model trajectory context in and for premature Remdesivir post
We can the turn Q&A. to Operator? call now over
